Hematologic malignancies following immune checkpoint inhibition for solid tumors

Area of Science:

• Oncology
• Immunology
• Hematology

Background:

• Immune checkpoint inhibition (ICI) offers durable responses for advanced cancers.
• Few cases link ICI to hematological malignancies post-treatment.
• This study investigates a potential association between anti-PD-1 therapy and myeloid cancers.

Purpose of the Study:

• To report and analyze cases of myeloid malignancies developing during or after anti-PD-1 therapy.
• To explore the hypothesis that PD-1 blockade may hasten the progression to overt myeloid cancers.
• To identify potential molecular mechanisms underlying this phenomenon.

Main Methods:

• Retrospective case series analysis of five patients treated between 2017-2021.
• Review of patient data for hematological neoplasia following anti-PD-1 treatment.
• Molecular analysis of pre-ICI samples for baseline myeloid gene variants.

Main Results:

• Five patients developed chronic myeloid leukemia (2), acute myeloid leukemia, myelodysplastic syndrome, or chronic eosinophilic leukemia.
• These conditions arose during or after anti-PD-1-based immunotherapy for solid tumors.
• Baseline molecular data from pre-ICI samples were analyzed.

Conclusions:

• Anti-PD-1 therapy may be associated with an increased risk or accelerated progression of myeloid malignancies.
• Further investigation into the mechanisms by which PD-1 blockade influences myeloid cancer development is warranted.
• This association requires careful consideration in clinical practice and future research.